Compositions and methods for dengue virus chimeric constructs in vaccines

Patent metadata

Field	Value
Publication number	US-10449231-B2
Application number	US-201715492981-A
Country	US
Kind code	B2
Filing date	Apr 20, 2017
Priority date	Mar 15, 2013
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

First claim

What is claimed:

1. A nucleic acid sequence comprising a nucleic acid sequence encoding a modified live, attenuated dengue-2 virus represented by SEQ ID NO:13 (WVS).

2. A pharmaceutical composition comprising the nucleic acid sequence according to claim 1 , and a pharmaceutically acceptable excipient.

3. A method for inducing an immune response in a subject comprising, administering the pharmaceutical composition of claim 2 to the subject, wherein the composition induces an immune response in the subject against at least one dengue virus serotype.

4. A vector comprising a nucleic acid sequence according to claim 1 .

5. The pharmaceutical composition according to claim 2 , further comprising one or more live, attenuated dengue viruses having a nucleotide sequence encoding a dengue virus or dengue virus chimera represented by SEQ ID NOS: 1, 3, 5, and 7, which is a dengue-1/dengue-2 chimera.

6. The pharmaceutical composition according to claim 2 , wherein the composition contains at least one, live attenuated dengue virus that represents each of the four dengue virus serotypes, wherein the composition is a tetravalent composition.

7. The pharmaceutical composition according to claim 2 , further comprising an immunogenic composition comprising a live, attenuated flavivirus selected from the group consisting of yellow fever virus, tick-borne encephalitis virus, Japanese encephalitis virus, West Nile virus, hepatitis C virus and a combination of two or more thereof.

8. A method for inducing an immune response in a subject comprising, administering the pharmaceutical composition of claim 5 to the subject, wherein the composition induces an immune response in the subject against at least one dengue virus serotype.

9. The method composition according to claim 8 , wherein the composition contains at least one, live attenuated dengue virus that represents each of the four dengue virus serotypes, wherein the composition is a tetravalent composition.

10. A kit comprising the immunogenic composition according to claim 5 , and a container.

11. A dengue-2 nucleic acid sequence represented by SEQ ID NO: 13 encoding species containing nucleotide G or C at nucleotide position 6481.

12. A dengue-2 nucleic acid sequence represented by SEQ ID NO:13 encoding species containing nucleotide C or T at nucleotide position 7156.

13. An isolated cell comprising at least one of the nucleic acid sequences according to claim 1 .

14. A method for manufacturing a pharmaceutical composition comprising, combining at least one of the nucleic acid sequences according to claim 1 and a pharmaceutically acceptable excipient and making a pharmaceutically acceptable composition for use in inducing an immune response against dengue virus in a subject.

Assignees

• Takeda Vaccines Inc
• Us Gov Health & Human Services

Inventors

• Stinchcomb Dan T
• Kinney Claire
• Kinney Richard M
• Livengood Jill A

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title